Myopia Progression in Children: A Parent-Friendly Evidence-Based Guide
Why myopia is rising globally, when to act, what works (atropine, orthokeratology, defocus glasses, soft contact lenses, outdoor time), and what to ask your child's eye doctor.
Why myopia matters now
Myopia is the most common refractive error worldwide and the leading cause of avoidable visual impairment in working-age adults. The IMI 2021 report projects nearly 5 billion myopic people by 2050, with about 1 billion at high risk of pathologic complications — myopic maculopathy, retinal detachment, glaucoma, and cataract. East-Asian school-age prevalence already exceeds 60%.
What is new in 2026 is that we can slow myopia progression by 30–70% in children, using interventions backed by level-1 evidence. The EyeToolkit Myopia Progression Predictor applies the IMI 2021 / Brennan 2020 model so parents and clinicians can quantify projected progression and compare intervention benefits.
What drives myopia progression
- Genetics — two myopic parents increase a child's risk ≈ 6×
- Lack of outdoor time — < 1.5 h/day is a strong independent risk factor
- Excessive near-work — especially continuous reading at < 30 cm
- Age of onset — earlier onset (age 6–8) predicts higher adult myopia
Evidence-based interventions (2026 update)
1. Outdoor time — the cheapest and most general intervention
The IMI 2021 clinical guidelines and the Sydney Myopia Study converge on at least 1.5–2 hours of outdoor light per day for all school-age children. The protective effect appears mediated by visible-light intensity rather than UV. (Xiong 2017, Holden 2021 IMI report)
2. Low-dose atropine (0.01–0.05%)
The ATOM2 and LAMP studies show 30–60% reduction in progression over 2–3 years, with minimal pupil-dilation side effects at 0.01%. Higher concentrations work better but produce more rebound after cessation. (Chua 2006, Yam 2019.)
3. Orthokeratology (OK lens / Ortho-K)
Rigid gas-permeable lenses worn overnight reshape the cornea. LAMP and ROMIO report 30–50% axial-length slowing over 2 years. Best suited for ≥ 6-year-olds with low-to-moderate myopia and adequate family support for lens care.
4. Defocus spectacles (DIMS / HOYA MiYOSMART)
Defocus Incorporated Multiple Segments (DIMS) spectacle lenses reduce progression by ~50% in 2-year RCTs. Practical for younger children who cannot tolerate contact lenses. (Lam 2020, Lam 2024 6-year follow-up.)
5. Soft defocus contact lenses (MiSight, Abiliti 1-Day)
Daily-disposable multifocal contact lenses with concentric treatment zones. CooperVision MiSight 3-year data show 59% reduction in spherical-equivalent progression. FDA-approved 2019 for age 8+.
6. Combination therapy
For fast progressors (e.g. > 1.00 D/year), combining atropine 0.01% with ortho-K or defocus lenses gives additional slowing versus monotherapy in small RCTs.
| Intervention | Approx. slowing | Age range | Notes |
|---|---|---|---|
| Outdoor time ≥ 2 h/day | ~20% | All ages | Population-level; cheap; cumulative |
| Atropine 0.01% | 30–50% | 4–14 | Daily drops; minimal rebound at low dose |
| Atropine 0.05% | 50–60% | 4–14 | Slightly more rebound; more pupil dilation |
| Ortho-K | 30–50% | 6–14 | Overnight wear; hygiene-dependent |
| DIMS / defocus spectacles | 50% | 6–14 | Daytime, comfortable for children |
| MiSight contact lenses | 59% | 8–14 | FDA-approved; daily disposable |
| Combination (atropine + optical) | 60–70% | 6–14 | For fast progressors; modest additional evidence |
What to ask at your child’s eye appointment
- What is my child's current refraction and axial length, and what is the trend over time?
- How fast is the progression? (Anything > 0.50 D/year is fast; > 0.75 D/year warrants intervention)
- What is the projected adult prescription at the current pace?
- Is my child a candidate for low-dose atropine, ortho-K, DIMS glasses, or MiSight lenses?
- What is the local experience and follow-up schedule for the chosen therapy?
- How should we monitor for side effects (atropine: glare, allergic reaction; OK lens: corneal staining)?
Use the calculator
The EyeToolkit Myopia Progression Predictor uses the IMI 2021 / Brennan 2020 population-mean model to project your child's refraction and axial length at age 18, and compares outcomes with and without each intervention tier. Educational only — discuss with your child's eye-care provider.
Frequently asked questions
At what age should my child be screened for myopia?
The American Academy of Pediatrics recommends vision screening at ages 3, 5, 6, 8, 10, 12, 15, and 18. If either parent is highly myopic, consider an earlier baseline (age 4–5) and annual checks from age 6.
Will my child need glasses forever?
Most myopic children continue to need correction into adulthood. The goal of myopia control is not to eliminate myopia but to reduce the final adult prescription and, more importantly, to keep axial length below the 26 mm threshold where pathologic risk rises sharply.
Is blue light from screens causing myopia?
There is no good evidence that blue light specifically causes myopia. The factor is time spent at near distances, regardless of light spectrum. What matters is taking breaks (20–20–20 rule), outdoor time, and physical activity.
Are at-home red-light therapy devices (low-level red light therapy) effective?
Early Chinese RCTs (Jiang 2021, 2022) reported large effects, but more rigorous follow-up has been mixed and there have been reports of retinal phototoxicity. The IMI 2026 update and AAO 2024 PPP do not yet endorse low-level red light therapy outside research settings.
When can my child stop treatment?
Treatment continues until axial-length progression slows below ~0.10 mm/year, typically by age 14–16. Some clinicians taper atropine gradually (e.g. 0.05% → 0.02% → 0.01%) to avoid rebound.
References
- Holden BA, et al. IMI — Report on Myopia Progression and Interventions. Invest Ophthalmol Vis Sci. 2021;62(5):2.
- Modjtahedi BS, et al. Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children. JAMA Ophthalmol. 2021;139(6):629-639.
- Chua WH, et al. Atropine for the treatment of childhood myopia (ATOM-2). Ophthalmology. 2006;113(12):2285-2291.
- Yam JC, et al. Low-dose Atropine for Myopia Progression (LAMP) Study. Ophthalmology. 2019;126(1):113-124.
- Lam CSY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: 6-year results. Br J Ophthalmol. 2024;108(8):1080-1085.
- Chamberlain P, et al. 3-year effectiveness of MiSight 1-day contact lenses for myopia control. Optom Vis Sci. 2019;96(8):556-567.
- Xiong S, et al. Time spent in outdoor activities in relation to myopia prevention and control in children. Br J Ophthalmol. 2017;101(4):395-401.
Educational content for parents and clinicians. Not a substitute for an in-person eye examination. Discuss options with a licensed eye-care provider.